摘要
目的分析研究冠心病介入治疗后心血管不良事件与应用替格瑞洛的预防效果。方法选取2015年3月~2016年10月收治的80例患者,将其随机分为观察组(40例)与对照组(40例),观察组患者使用替格瑞洛进行治疗,对照组患者使用氯吡格雷进行治疗,分别进行用药后,对比观察两组患者的不良反应发生率及术后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)等凝血功能指标。结果两组患者的凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)等凝血功能指标均无明显差异(P>0.05),但使用替格瑞洛进行治疗的观察组患者不良反应发生率(5.00%)远远低于使用氯吡格雷进行治疗的对照组患者(27.50%),且P<0.05,差异具有统计学意义。结论给予冠心病介入治疗患者使用替格瑞洛进行治疗,未对患者凝血功能造成影响,同时,降低了术后心血管不良事件发生率,值得应用推广。
Objective To study the interventional therapy of coronary heart disease and cardiovascular adverse events and application for the prevention effect of Grillo. Methods 80 patients in our hospital from March 2015 to October 2016, which were randomly divided into observation group and control group, 40 patients in each group, the observation group was treated with ticagrelor treatment, patients in the control group were treated with clopidogrel, respectively after treatment, the occurrence of adverse reactions of the two groups than observation the patient＇s prothrombin time （PT）, activated partial thromboplastin time （ APTF）, thrombin time （ TT）, fibrinogen （ FIB ） and blood coagulation indexes. Results Two groups of patients with prothrombin time （ PT ）, activated partial thromboplastin time （ APTT ）, thrombin time （TT）, fibrinogen （FIB） were not significantly difference of coagulation index （P 〉 0.05 ）, but the use of ticagrelor the adverse reaction of the patients in the observation group the incidence rate （5%） is far lower than the use of clopidogrel in the control group （27. 50% ）, and P 〈0. 05, the difference was statistically significant. Conclusions The use of ticagrelor treatment intervention in patients with coronary heart disease, not only did not affect blood coagulation function in patients, but also reduce the postoperative incidence of adverse cardiovascular events, and is worth popularizing.
出处
《航空航天医学杂志》
2017年第7期805-807,共3页
Journal of Aerospace medicine
关键词
冠心病
氯吡格雷
心血管不良事件
Coronary heart disease
Clopidogrel
Adverse cardiovascular events
